Galmed Pharmaceuticals Ltd expected to post a loss of 16 cents a share - Earnings Preview

Eocene

16/12/2022 13:38

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show no change in quarterly revenue when it reports 
results on December 19 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Galmed
Pharmaceuticals
Ltd is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $1​, above​ its last closing price
of $0.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.17       -0.16      -0.21     Missed  -27.3
 Jun. 30 2022  -0.24       -0.24      -0.15     Beat    36.4
 Mar. 31 2022  -0.32       -0.32      -0.24     Beat    25​
 Dec. 31 2021              -0.30      -0.30     Met     0.8
 ​​Sep.        -0.37       -0.36      -0.31     Beat    13.4
 30 2021                                                
 Jun. 30 2021  -0.41       -0.38      -0.33     Beat    13.6​
 Mar. 31 2021  -0.42       -0.38      -0.38     Met     1.3
 Dec. 31 2020  -0.35       -0.36      -0.48     Missed  -31.9
 This summary was machine generated December 16 at 13:38 GMT. 
All figures in US dollars  unless otherwise stated